Article
Molecular markers in lung cancer: role of EBUS.
Current opinion in pulmonary medicine - 1 May 2017
Bilaçeroğlu Semra
Abstract excerpt
PURPOSE OF REVIEW: As demonstrated by the recent therapeutic advances in nonsmall cell lung cancer (NSCLC), a personalized approach can considerably reduce its mortality. RECENT FINDINGS: Molecular tests identifying genetic mutations in NSCLC have led to a shift towards more effective and personalized therapies targeted to these alterations. Adequate tissue is required for diagnosing, subcharacterizing, and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
